Introduction {#s1}
============

GIPC1 (GAIP interacting protein, C-terminus 1) and its two paralogs GIPC2 and GIPC3 are universal adaptor proteins that bind and regulate vesicular trafficking of many transmembrane proteins ([@bib27]). Based on the cargo proteins it interacts with, GIPC1 is also named syndecan-4 binding protein (Synectin), Neuropilin-1-interacting protein (NIP), insulin-like growth factor-1 receptor interacting protein (IIP1), GLUT1 C-terminal binding protein (GLUT1CBP), M-SemF cytoplasmic domain-associated protein (SEMCAP-1) and Tax-interacting protein 2 (TIP2) ([@bib8]; [@bib10]; [@bib18]; [@bib31]; [@bib46]; [@bib58]). GIPCs contribute to the endocytosis process by tethering the cargo proteins on endocytic vesicles to the motor protein myosin VI ([@bib8]; [@bib38]; [@bib44]). Myosin VI is the only known actin-based motor that walks toward the minus/pointed end of actin filaments and therefore is specialized at transporting endocytic vesicles inward from the cell cortex ([@bib51]; [@bib52]). Myosin VI and GIPCs also contribute to earlier steps of endocytosis, including facilitating the formation of clathrin-coated pits and clustering ligand-bound cell surface receptors into the pits ([@bib21]). Another function of the GIPC/myosin VI complex is to act as an anchor on the cell surface. This function is critical for maintaining the structural integrity of stereocilia in the inner ear, and many mutations of GIPC3 or myosin VI have been found to cause familial hearing loss ([@bib27]).

GIPCs contain a central PDZ (PSD-95, Dlg and ZO-1) domain that mediates the interaction with the C-terminal PDZ-binding motif (PBM) in cargo proteins. While the general rules of specificity in PDZ/PBM interactions are well understood ([@bib63]), the mechanisms by which GIPCs distinguish their cargo proteins from many proteins containing similar PBMs were unclear. The PDZ domain in GIPCs is flanked by a N-terminal GIPC-homology 1 (GH1) domain and a C-terminal GH2 domain ([@bib27]). The GH1 and GH2 domains are unique to the GIPC family and lack obvious sequence similarity to other proteins. The GH1 and PDZ domains together mediate oligomerization of GIPCs ([@bib8]; [@bib18]; [@bib26]; [@bib28]; [@bib44]). The mechanisms of the oligomerization and its role in the regulation of GIPCs remained unclear. The GH2 domain mediates the interaction with myosin VI ([@bib38]; [@bib44]). Cargo binding to the PDZ domain in GIPC1 promotes the interaction with myosin VI, suggesting that the two binding events in GIPCs are regulated and communicate with each other through a steric or allosteric mechanism ([@bib38]).

Myosin VI contains a motor domain, an IQ motif domain, a coiled-coil region, and a C-terminal cargo-binding (CBD) domain. The motor activity of myosin VI is normally suppressed by autoinhibition, which can be released by binding of adaptor proteins through a mechanism that is poorly understood ([@bib17]). An 'RRL' (single-letter amino acid code) motif between the coiled-coil and CBD in myosin VI is critical for binding to GIPCs ([@bib23]; [@bib50]; [@bib61]), but the mode of the interaction was unknown. Processive walking of myosin VI along actin filaments requires its dimerization, mediated by both the coiled-coil and binding of adaptor proteins ([@bib34]; [@bib41]; [@bib43]; [@bib50]; [@bib64]). Larger oligomers of myosin VI have been implicated in coordinated long-distance runs over dense and interlaced actin networks ([@bib49]). Hence, oligomerized GIPCs may play a role in both releasing the autoinhibition and promoting the oligomerization of myosin VI, but the underlying mechanisms were unclear.

The transmembrane receptor PlexinD1 contains a C-terminal 'SEA' motif that constitutes a PBM and interacts with GIPC1 ([@bib19]). The plexin family proteins are the major receptors for the guidance molecules semaphorins. Semaphorin-activated plexin primarily transduces repulsive guidance signal that is critical for the development of the nervous and cardiovascular systems ([@bib56]). Semaphorin binding induces the formation of the active dimer of plexin ([@bib25]; [@bib32]; [@bib39]). The dimerization activates the GTPase-activating protein (GAP) domain in the plexin cytoplasmic region (referred to as plexin~cyto~ thereafter), which transduces the signal by switching off the small GTPase Rap ([@bib22]; [@bib60]; [@bib59]). Plexin~cyto~ also contains a Juxtamembrane segment (JM-segment) and a Rho GTPase Binding Domain (RBD) that both play regulatory roles in signaling ([@bib6]; [@bib22]; [@bib54], [@bib55]). Semaphorin-stimulated endocytosis of plexin contributes to the repulsive guidance function ([@bib16]; [@bib53]). A recent study has shown that GIPC1-mediated endocytic trafficking and sorting of Sema3E-activated PlexinD1 play important regulatory roles in PlexinD1 signaling ([@bib9]).

Structures of plexins, the PDZ domain of GIPC2 (PDB ID: 3GGE) and the GIPC-binding region in myosin VI have been reported previously ([@bib6]; [@bib23], [@bib22]; [@bib55]; [@bib60]; [@bib59]; [@bib61]). However, structures of full-length GIPCs and their complexes with either cargos or myosin VI are not available, hindering our understanding of the mechanisms underlying GIPC functions. In this study, we present comprehensive structural analyses of PlexinD1~cyto~, GIPCs and myosin VI in the apo and bound states. The structures and associated mutational analyses elucidate the structural basis and regulation mechanisms for the interaction between PlexinD1 and GIPC1. In addition, the structures reveal an unanticipated mechanism for high-order oligomerization of GIPCs and myosin VI, which may underlie the clustering on the plasma membrane and efficient endocytic transport of PlexinD1 and other cargo proteins by GIPCs and myosin VI.

Results {#s2}
=======

Structure of GIPC1 in the dimeric and autoinhibited state {#s2-1}
---------------------------------------------------------

We crystallized the GH1-PDZ-GH2 domains of mouse GIPC1 and determined its X-ray crystal structure to 1.9 Å resolution ([Figure 1](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). The structure of the PDZ domain of GIPC1 is similar to that of the isolated PDZ domain of GIPC2 (PDB ID: 3GGE), featuring a typical PDZ fold with five β-strands and two α-helices ([Figure 1C](#fig1){ref-type="fig"}). The GH1 domain adopts an ubiquitin-like fold composed of four β-strands and one α-helix, although it lacks obvious sequence similarity to ubiquitin ([Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). The GH2 domain forms a four-helix globular fold ([Figure 1C](#fig1){ref-type="fig"}).10.7554/eLife.27322.002Figure 1.Crystal structure of mouse GIPC1 in the autoinhibited conformation.(**A**) Domain structure of mouse GIPC1 and cartoon representation of the overall architecture of the domain-swapped dimer. The color scheme for one subunit in the dimer of the cartoon representation is the same as in the domain structure. The other subunit is colored gray. (**B**) Two orthogonal views of the GIPC1 structure. The dotted lines indicate the disordered portion of the linker between the PDZ and GH2 domains. The color scheme is the same as in (**A**). (**C**) Expanded views of the individual domains.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.002](10.7554/eLife.27322.002)10.7554/eLife.27322.003Figure 1---figure supplement 1.Representative electron density of the apo-GIPC1 structure.The sigma-A weighted 2F~o~-F~c~ map for helix α1 and loop(α1- α2) in the GIPC1-GH2 domain is shown, contoured at 1.0 sigma.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.003](10.7554/eLife.27322.003)10.7554/eLife.27322.004Figure 1---figure supplement 2.Sequence alignment of GIPC1, 2 and 3.The secondary structure and domain boundary assignments are based on the apo-GIPC1 structure. Residue numbering is based on mouse GIPC1. The GH1, PDZ, PDZ-GH2 linker and GH2 domains are denoted by background color of yellow, orange, light green and magenta, respectively. The black circles and stars highlight key residues in binding interfaces I and II for myosin VI-HCBD that were tested by mutational analyses. h, human; m, mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.004](10.7554/eLife.27322.004)10.7554/eLife.27322.005Table 1.Data collection and refinement statistics.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.005](10.7554/eLife.27322.005)GIPC1PlexinD1PlexinD1/\
GIPC1 complexGIPC1-GH2/ myosin\
VI-HCBD complexGIPC2-GH2/ myosin\
VI-HCBD complex**Data collection**Space groupP2~1~P2~1~P6~1~22I222C2**Cell dimensions**a, b, c (Å)45.4, 77.6, 80.369.9, 164.5, 84.399.8, 99.8, 531.9115.0, 164.1, 171.8171.8, 53.2, 122.8α, β, γ (°)90.00, 89.95, 90.0090.00, 99.47, 90.0090.00, 90.00, 120.0090.00, 90.00, 90.0090.00 108.23 90.00Content of the asymmetric unitGIPC1 dimer, 1PlexinD1, 2PlexinD1, 1; GIPC1, 1GH2, 5; HCBD, 5GH2, 5; HCBD, 5Resolution (Å)50.0--1.90 (1.93--1.90)\*50.0--2.70 (2.75--2.70)50.0--3.20 (3.26--3.20)50.0--3.5 (3.56--3.50)50--3.6 (3.66--3.60)R~sym~ (%)6.2 (56.1)7.2 (38.8)14.1 (81.9)15.7(\>100)15.9 (47.2)R~pim~(%)3.4 (31.9)4.2 (23.1)4.1 (36.8)7.4 (49.3)7.9 (27.2)*I*/σ21.3 (2.1)29.9 (3.4)17.5 (2.0)10.3 (1.6)11.0 (2.7)CC~1/2~^\#^0.7820.9220.6790.6530.859Completeness (%)100.0 (100.0)99.4 (96.8)100.0 (100.0)98.1 (97.0)98.7 (95.4)Redundancy4.1 (4.0)3.9 (3.6)12.0 (5.6)6.1 (6.0)4.7 (3.7)**Refinement**Resolution (Å)40.1--1.9 (1.95--1.90)37.1--2.7 (2.77--2.70)48.0--3.2 (3.28--3.20)47.1--3.5 (3.60--3.50)42.9--3.6 (3.79--3.60)No. reflections406234717126781187089763*R*~work~/*R*~free~ (%)13.6 (19.4)/17.5 (24.8)21.5 (31.8)/25.6 (36.9)17.9 (29.3)/21.6 (32.4)18.7 (26.8)/24.0 (32.3)21.3 (26.6)/27.8 (37.6)No. atomsProtein41208092541648584590Ligand/ion003500Water645981900B-factorsProtein21.980.057.870.457.8Ligand/ion115.2Water33.561.025.7R.m.s deviationsBond lengths (Å)0.0060.0030.0050.0070.003Bond angles (°)0.92760.6170.8340.8230.603Ramanchandran plotFavored (%)96.596.296.794.196.2Allowed (%)3.53.63.25.93.7Disallowed (%)00.20.100.2[^1][^2]

A prominent feature of the GIPC1 structure is that two molecules in the asymmetric unit form a domain-swapped dimer ([Figure 1](#fig1){ref-type="fig"}). The domain swap is the result of an exchange of the last β-strand between the two GH1 domains ([Figure 1C](#fig1){ref-type="fig"}). The segment N-terminal to the last β-strand of one GH1 domain meets its counterpart of the other GH1 domain, making extensive intermolecular interactions at the dimer interface. The extension N-terminal to the GH1 domain also contributes to the dimer interface. Due to the domain swap, the PDZ domain from one molecule is located in close proximity to the GH1 domain of the dimer partner. The two domains form an integrated structural module through extensive interactions, further stabilizing the architecture of the GIPC1 dimer. The overall shape of the dimeric GH1-PDZ module resembles a canoe with the two GH1 domains at the middle and the two PDZ domains curving upwards at each end. The PBM-binding groove between helix α2 and strand β2 in the PDZ domain is placed at the concave upper face of the canoe-like dimer ([Figure 1](#fig1){ref-type="fig"}). This dimeric configuration provides a structural basis for the previously reported self-association of GIPC1 ([@bib8]; [@bib18]; [@bib26]; [@bib28]; [@bib44]). The high degree of sequence similarity in the GIPC family suggests that GIPC2 and GIPC3 also form similar domain-swapped dimers ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).

The C-terminal portion (residues 236--257) of the PDZ-GH2 linker is well structured and contains two short β-strands, which together with a small segment in GH1 forms a small three-stranded β-sheet ([Figures 1](#fig1){ref-type="fig"} and [2A](#fig2){ref-type="fig"}). However, the N-terminal portion (residues 219--235) of the linker is disordered, making the connection between the PDZ and linker of the two subunits in the dimer ambiguous. We tentatively assigned the connection as shown in [Figure 1A and B](#fig1){ref-type="fig"}, in which the span of the disordered region in the linker is \~20 Å. Based on this assignment, one linker-GH2 packs against the GH1 domain from the same subunit as well as the PDZ domain from the other subunit. The alternative connection is less likely but possible, as the gap of \~40 Å in this configuration can be spanned by the 17-residue disordered linker region. The GH2 domain wedges itself between the PDZ-GH2 linker and the PDZ domain, reminiscent of a passenger sitting in the canoe formed by the dimeric GH1-PDZ modules. Notably, the loop between helices α1 and α2 in the GH2 domain partially occupies the PBM-binding groove in the PDZ domain ([Figure 2B](#fig2){ref-type="fig"}). Conversely, the PDZ domain blocks one face on the GH2 domain that binds myosin VI (as defined by the structures of the GH2/myosin VI complexes below). The apo-GIPC1 structure therefore represents an autoinhibited conformation that hinders binding to both PBM-containing cargo proteins and myosin VI.10.7554/eLife.27322.006Figure 2.Autoinhibitory interactions mediated by the linker-GH2 domains in the apo-GIPC1 structure.(**A**) Interactions of the linker with the GH1 and GH2 domains. (**B**) Interaction between the GH2 and PDZ domains. The loop between helices α1 and α2 in the GH2 domain that partially blocks the PBM binding site is labeled 'loop(α1-α2)' and highlighted in cyan.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.006](10.7554/eLife.27322.006)

Structure of the PlexinD1/GIPC1 complex {#s2-2}
---------------------------------------

The JM segment in plexin~cyto~ is relatively flexible and can adopt multiple conformations for regulating plexin activity ([@bib6]; [@bib22]; [@bib42]; [@bib55]; [@bib60]). While full-length PlexinD1~cyto~ failed to crystallize, we crystallized and determined the structures of a construct with the JM segment truncated (still referred to as PlexinD1~cyto~ for simplicity), both in the apo-form (to 2.7 Å resolution) and in complex with GIPC1 (to 3.2 Å resolution) ([Figure 3](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). The overall structure of apo-PlexinD1~cyto~ are similar to other plexin~cyto~ structures reported previously ([Figure 3B](#fig3){ref-type="fig"}) ([@bib6]; [@bib22]; [@bib42]; [@bib55]; [@bib60]). The RBD forms an independent ubiquitin-like domain that packs against one side of the GAP domain. The two GAP-homology regions (C1 and C2) fold together to form the GAP domain ([Figure 3A and B](#fig3){ref-type="fig"}). The GAP domain of plexins contains a regulatory element referred to as the activation segment, which toggles between the closed inactive and open active conformations under the control of plexin dimerization ([@bib60]). The activation segment in the PlexinD1~cyto~ structure appears partially open ([Figure 3B](#fig3){ref-type="fig"}), although it was crystallized in the monomeric state. The relatively high basal GAP activity of PlexinD1 may be due to this propensity of the activation segment to adopt the open conformation ([@bib59]).10.7554/eLife.27322.007Figure 3.Crystal structure of PlexinD1~cyto~ and the PlexinD1~cyto~/GIPC1 complex.(**A**) Domain structure of mouse PlexinD1. The extracellular and transmembrane regions in PlexinD1 are omitted. The crystallization construct includes the regions denoted by the solid boxes. The single-letter amino acid sequence of the PBM is shown. (**B**) Comparison of the structures of apo-PlexinD1~cyto~ and PlexinD1~cyto~ from the PlexinD1~cyto~/GIPC1 complex. (**C**) Two orthogonal views of the PlexinD1~cyto~/GIPC1 complex structure. The dotted lines in green indicate the connection to the membrane by the transmembrane and juxtamembrane (JM) regions of PlexinD1. The linker-GH2 domains in GIPC1, invisible in the structures, are drawn as cartoons. Plx, Plexin.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.007](10.7554/eLife.27322.007)10.7554/eLife.27322.008Figure 3---figure supplement 1.Electron-density maps for the PBM region in the structures of (**A**) apo-PlexinD1 and (**B**) PlexinD1 in complex with GIPC1.The sigma-A weighted 2F~o~-F~c~ maps are contoured at 1.0 sigma.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.008](10.7554/eLife.27322.008)10.7554/eLife.27322.009Figure 3---figure supplement 2.Gel analysis of crystals of the PlexinD1/GIPC1 complex.Many crystals were collected, washed with the crystallization buffer three times and analyzed by SDS-PAGE. PlexinD1~cyto~ (\~66 kDa) and GIPC1 (\~36 kDa) ran at their respective expected molecular weight, demonstrating that both proteins were intact in crystals.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.009](10.7554/eLife.27322.009)10.7554/eLife.27322.010Figure 3---figure supplement 3.Comparison of the domain-swapped dimer of the GH1-PDZ domains from apo-GIPC1 and the PlexinD1/GIPC1 complex.The two structures are superimposed on the PDZ domain on the left. The red arrows indicate the conformational difference at the other end of the dimer. The PDZ-GH2 linker and GH2 domain in the apo-GIPC1 structure are omitted for clarity.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.010](10.7554/eLife.27322.010)

The structure of PlexinD1~cyto~ in complex with GIPC1 is similar to apo-PlexinD1~cyto~, except in the C-terminal tail that binds GIPC1 ([Figure 3B](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}; see details below). The entire PDZ-GH2 linker and GH2 domain of GIPC1 in the PlexinD1~cyto~/GIPC1 complex are invisible in the electron-density map. A gel analysis shows that the GIPC1 protein is intact in crystals ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}), suggesting that the linker-GH2 domains are present but completely disordered in the PlexinD1/GIPC1 complex structure. As mentioned above, the PDZ and GH2 domains mutually inhibit each other in the autoinhibited apo-structure of GIPC1. Binding of PlexinD1 to GIPC1 is expected to dislodge the GH2 domain from its autoinhibitory interaction with the PDZ domain, rendering the GH2 domain and the PDZ-GH2 linker conformationally flexible in relation to the GH1-PDZ module ([Figure 3C](#fig3){ref-type="fig"}). As a result, the GH2 domain can more readily interact with myosin VI, which explains the enhanced recruitment of myosin VI by GIPC1 when GIPC1 is bound to cargo proteins as reported previously ([@bib38]).

The GH1 and PDZ domains of GIPC1 in the PlexinD1/GIPC1 complex are well structured and form the same domain-swapped dimer as apo-GIPC1 ([Figure 3C](#fig3){ref-type="fig"}). The curvature of the canoe-shaped dimer is, however, different in the two structures, suggesting that the dimer interface between the two GH1 domains has a certain degree of plasticity ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). The variation of the dimer interface in the PlexinD1~cyto~/GIPC1 complex structure could result from the loss of the interfacial interactions made by the PDZ-GH2 linker present in the apo-GIPC1 structure. The two PlexinD1~cyto~ molecules are placed at the opposite sides of the GIPC1 dimer and do not contact each other ([Figure 3C](#fig3){ref-type="fig"}). Simple modeling shows that the 2:2 PlexinD1/GIPC1 complex is compatible with full-length PlexinD1 in lipid membrane interacting with GIPC1 in the cytosol, which can use its flexibly attached GH2 domain to recruit myosin VI ([Figure 3C](#fig3){ref-type="fig"}).

In the apo-PlexinD1~cyto~ structure, the C-terminal tail region (residues 1916--1925) constitutes the C-terminal part of the last helix in the GAP domain, except for the last two residues (Glu1924 and Ala1925) which are disordered ([Figure 3B](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). In contrast, the tail segment in the PlexinD1~cyto~/GIPC1 complex adopts an ordered, extended conformation ([Figure 3B](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). As expected, the PBM interacts with the PDZ domain in GIPC1 in the typical PBM/PDZ-binding mode, where the PBM forms a short β-strand to pack in an anti-parallel fashion with strand β2 in the PDZ domain ([Figure 4A](#fig4){ref-type="fig"}) ([@bib63]). The sidechain of the very C-terminal residue (Ala1925) in the PBM is buried in the hydrophobic pocket between helix α2 and strand β2 of the PDZ domain, while its carbonyl group interacts with the backbone atoms of Leu143 and Gly144 in the PDZ domain. Ser1923 and Glu1924 in the PBM contribute to the specific binding by interacting with His191 and Thr146/Arg159 respectively in the PDZ domain. In addition to these canonical PBM/PDZ interactions, GIPC1 makes extensive contacts with other residues in the C-terminal tail as well as the two preceding helices of PlexinD1, resulting in a large interface with the total buried surface area of 2072 Å^2^ ([Figure 4A](#fig4){ref-type="fig"}). Notably, Ile1918 and Y1919 in the tail of PlexinD1 plug into a hydrophobic pocket formed at the junction between the GH1 and PDZ domain. Glu1920, Cys1921 and Tyr1922 in the PlexinD1 tail are sandwiched between the PlexinD1 GAP domain and GIPC1, making additional Van der Waals and polar interactions. Most residues involved in these interactions are highly conserved in PlexinD1 from different species but divergent in other plexin family members ([Figure 4B](#fig4){ref-type="fig"}), supporting the functional relevance of these interactions ([@bib9]; [@bib19]). These additional interactions likely enhance the affinity and specificity between PlexinD1 and GIPC1. This dual binding mode is analogous to the interaction between class B plexins and PDZ-RhoGEF where the secondary interface significantly increases the binding affinity ([@bib42]). A superimposition of the PlexinD1~cyto~/GIPC1 complex with apo-GIPC1 shows that the GH2 domain sterically clashes with PlexinD1 ([Figure 4C](#fig4){ref-type="fig"}), supporting the notion that the GH2 domain in apo-GIPC1 is autoinhibitory and must dissociate before PlexinD1 can bind.10.7554/eLife.27322.011Figure 4.Interactions between PlexinD1 and GIPC1.(**A**) Detailed views of the interfaces. The top right panel highlights the packing interactions between the PlexinD1-PBM and GIPC1. The I1918/Y1919 motif in the PMB is accommodated by a hydrophobic pocket between the GH1 and PDZ domains in GIPC1. The lower right panel shows detailed interactions between the PlexinD1-PBM and GIPC1. The lower left panel shows the additional interface between the PlexinD1-GAP domain and the GIPC1-PDZ domain. (**B**) Sequence alignment of the C-terminal region of PlexinD1 from different species and other plexin family members. Residue numbers are based on mouse PlexinD1. (**C**) Superimposition of the structures of the PlexinD1~cyto~/GIPC1 complex and apo-GIPC1 based on the PDZ domain. It is evident that the GIPC1-GH2 domain in the apo-GIPC1 structure clashes with PlexinD1 bound to GIPC1. Plx, Plexin.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.011](10.7554/eLife.27322.011)

Structure and oligomerization of the GH2/myosin VI complex {#s2-3}
----------------------------------------------------------

The 'RRL' motif in myosin VI is critical for the interaction with GIPC1 ([@bib50]), but the precise GIPC-binding region was not mapped. We purified various segments of mouse myosin VI containing the 'RRL' motif fused with glutathione sulfur transferase (GST). While longer constructs tended to degrade, the GST-fusion of a conserved 45-residue segment (residues 1052--1096, 'HCBD' in [Figure 5A](#fig5){ref-type="fig"}; residue numbers based on the short isoform of myosin VI) was stable and interacted with the GH2 domains from all three GIPCs (See below). These observations are consistent with two recent studies showing that this region in myosin VI forms a compact helical domain and is sufficient for GIPC1 binding ([@bib23]; [@bib61]). Here, we refer to the 1052--1096 region of myosin VI the helical cargo-binding domain (HCBD) to distinguish it from the C-terminal canonical CBD. We determined the crystal structures of the myosin VI-HCBD in complex with the GH2 domain from GIPC1 and GIPC2, respectively ([Figure 5](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). The two structures are highly similar ([Figure 5B and C](#fig5){ref-type="fig"}), and the following discussions will refer to the GIPC1-GH2/myosin VI complex unless otherwise stated.10.7554/eLife.27322.012Figure 5.Crystal structures of the GH2 domains from GIPC1 and GIPC2 in complex with the myosin VI-HCBD.(**A**) Domain structure of mouse myosin VI. The HCBD is drawn larger than its proportion. (**B**) Structure of the GIPC1-GH2/myosin VI-HCBD complex. The five GH2/HCBD units in the asymmetric unit are shown. The N- and C-termini of one HCBD are labeled. Interfaces I and II between the GIPC1-GH2 and myosin VI-HCBD domains are displayed in detail in the two expanded views, respectively. (**C**) Overall structure of the GIPC2-GH2/myosin VI-HCBD complex. The five GH2/HCBD units in the asymmetric unit are shown. (**D**) Superimposition of one GH2/HCBD unit to the apo-GIPC1 structure. The superimposition is based on the GH2 domain. For clarity, only one GH2 and PDZ from the apo-GIPC1 structure are shown. It is evident that the PDZ domain in the apo-GIPC1 structure clashes with the myosin VI-HCBD bound to interface I of the GH2 domain.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.012](10.7554/eLife.27322.012)10.7554/eLife.27322.013Figure 5---figure supplement 1.Electron-density maps for the HCBD in the structures of (**A**) the GIPC1-GH2/myosin VI-HCBD complex and (**B**) the GIPC2-GH2/myosin VI-HCBD complex.The sigma-A weighted 2F~o~-F~c~ maps are contoured at 1.0 sigma.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.013](10.7554/eLife.27322.013)10.7554/eLife.27322.014Figure 5---figure supplement 2.Crystal packing of (**A**) the GIPC1-GH2/myosin VI-HCBD complex and (**B**) the GIPC2-GH2/myosin VI-HCBD complex.In each, one chain of alternating GH2 (pink) and HCBD (olive) are highlighted. Three asymmetric units (each containing 5 GH2/HCBD pairs) are displayed for each structure.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.014](10.7554/eLife.27322.014)10.7554/eLife.27322.015Figure 5---figure supplement 3.Comparison of interfaces I and II in the structures of the GIPC1-GH2/myosin VI-HCBD and GIPC2-GH2/myosin VI-HCBD complexes.(**A**) The five unique copies of the HCBD in the asymmetric unit of the crystal of the GIPC1-GH2/myosin VI-HCBD complex are superimposed. This operation led to well alignment of all the GH2 domains bound to these HCBD molecules, highlighting the fact that all the HCBD molecules in the crystal interact with the GIPC1-GH2 domain in the same modes through either interface I or II. (**B**) The same superimposition as in (**A**) was applied to the GIPC2-GH2/myosin VI-HCBD structure, showing that both interfaces I and II are highly similar to those in the GIPC1-GH2/myosin VI-HCBD structure.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.015](10.7554/eLife.27322.015)10.7554/eLife.27322.016Figure 5---figure supplement 4.Interference of the GIPC-GH2/myosin VI-HCBD interaction by the insert helix in the longer version of myosin VI.The structure of the longer version of myosin VI (PDB ID: 2N12) is superimposed to the HCBD in the GIPC1-GH2/myosin VI-HCBD complex. The two molecules of the GH2 domain, interacting with the HCBD through interfaces I and II, respectively, are shown. The insert helix (red) clashes severely with the GH2 domain bound at interface II, and with that bound at interface I to a lesser extent.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.016](10.7554/eLife.27322.016)

The HCBD of myosin VI adopts the same two-helix conformation as seen in the recent NMR structure (PDB ID: 2N10), with the 'RRL' motif located at the center of the second helix ([Figure 5B](#fig5){ref-type="fig"}) ([@bib23]; [@bib61]). The GH2 domain of GIPC1 in complex with the myosin VI-HCBD is similar to that in the apo-GIPC1 structure. There are five copies of both myosin VI-HCBD and GIPC1-GH2 molecules in each asymmetric unit, arranged in an alternating pattern ([Figure 5B](#fig5){ref-type="fig"}). The group of five HCBD and GH2 domains repeats itself in the neighboring unit cell, yielding a continuous array of alternating HCBD and GH2 that extends throughout the crystal ([Figure 5---figure supplement 2A](#fig5s2){ref-type="fig"}). Considering one GH2/HCBD pair as a unit, the neighboring units in the array are related roughly by a five-fold right-handed rotational symmetry and a \~22 Å translation. The GIPC2-GH2/myosin VI structure forms the same alternating array, despite being crystallized in a different condition and space group ([Figure 5C](#fig5){ref-type="fig"} and [Figure 5---figure supplement 2B](#fig5s2){ref-type="fig"}). The recurrence of this repeating array argues strongly that this arrangement captures the oligomeric interaction mode between GIPCs and myosin VI that is relevant to function, rather than being a crystal packing artifact. The alternative arrays mediated by the bivalent interactions seen here suggest an unanticipated mechanism for high-order oligomerization of the GIPC/myosin VI complex. The oligomer may collect multiple myosin VI molecules to enhance the processive transport of endocytic vesicles on actin filaments, as suggested by the observation that multiple myosin VI dimers attached to the same cargo can coordinate their movements to drive long-distance runs over interlaced actin networks ([@bib49]). Previous studies have suggested that GIPC1 and myosin VI contribute to clustering of cell surface receptors into clathrin-coated pits at the initial stage of endocytosis in certain cell types, particularly those with microvilli ([@bib21]). In such cells, high-order oligomerization of GIPC1 and myosin VI may make this process more efficient. The anchoring function of the GIPC3/myosin VI complex for stereocilia in the inner ear may also benefit from the enhanced mechanical strength provided by the high-order oligomerization ([@bib52]).

Due to the fivefold rotational symmetry, GH2 molecules in the GH2/HCBD oligomer assume five different orientations ([Figure 5B and C](#fig5){ref-type="fig"}). Considering both the structures of the PlexinD1~cyto~/GIPC1 and GH2/HCBD complexes in the context of the lipid membrane, the \~40 residue flexible PDZ-GH2 linker in GIPCs can readily bridge the distance between the PlexinD1-bound PDZ domain and the GH2 domain in the GH2/HCBD oligomer regardless of the relative orientation of the GH2 domain. Likewise, the predicted flexible regions surrounding the HCBD in myosin VI allow differently oriented HCBDs in the oligomer to connect to the motor domains walking on one or multiple actin filaments. Oligomerization with combinations of translational and rotational symmetries is also seen in the kinase domains of the EGF receptor and the endoplasmic reticulum (ER) stress sensor IRE1, which are transmembrane proteins located on the plasma and ER membrane, respectively ([@bib24]; [@bib29]). In these cases, the flexibility in various linkers has also been proposed to allow differently oriented kinase molecules to converge at the membrane surface and connect to the transmembrane region of the proteins.

Interactions in the two interfaces between the GIPC-GH2 and myosin VI-HCBD domains {#s2-4}
----------------------------------------------------------------------------------

The bivalent interactions between the GIPC-GH2 and myosin VI-HCBD are mediated by two distinct interfaces ([Figure 5B](#fig5){ref-type="fig"} and [Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). Interface I involves the two loops in the GIPC-GH2 domain, one between helices α1 and α2 and the other between helices α3 and α4 ([Figure 5B](#fig5){ref-type="fig"}). These two loops interact with Arg1084 and Arg1085 in the 'RRL' motif on one side of the second helix in the myosin VI-HCBD. In addition, hydrophobic residues such as Val1088, Tyr1089 and Trp1092 on the same side of the second helix in the myosin VI-HCBD dock on the hydrophobic patch formed by Tyr275, Met276, Ile278, Leu283, Phe311, etc. in the GIPC1-GH2 domain. Interface I is further expanded by the first helix and the N-terminal extension in the myosin VI-HCBD. Interface II is formed on the opposite side of the HCBD with helix α4 and the N-terminal end of helix α3 in the GIPC1-GH2 domain ([Figure 5B](#fig5){ref-type="fig"}). Tyr1059 and Leu1086 (the 'L' in the 'RRL' motif) in the myosin VI-HCBD are sandwiched between interfaces I and II. Phe1082 and Leu1086 from the myosin VI-HCBD and Pro297, Phe319, Trp322 and Gly323 from the GIPC1-GH2 domain together form the hydrophobic core of interface II. There are also several charge- and hydrogen bond-mediated interactions. Interfaces I and II bury \~1300 and \~1100 Å^2^ solvent accessible surface area, respectively. The two interfaces in the GIPC2-GH2/HCBD complex structure are highly similar to those in the GIPC1-GH2/HCBD complex ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}).

As mentioned above, the loop between helices α1 and α2 in the GH2 domain blocks the PBM-binding site on the PDZ domain in the apo-GIPC1 structure ([Figure 2B](#fig2){ref-type="fig"}). Conversely, the inter-domain interaction prevents this loop from forming interface I with HCBD in myosin VI ([Figure 5D](#fig5){ref-type="fig"}). Therefore, the apo-GIPC1 structure represents the state in which the PDZ and GH2 domains mutually inhibit each other. Interface II in the GH2 domain in the autoinhibited structure of GIPC1 is open for interacting with myosin VI. It is unclear at present whether and how the interface-II-mediated interaction is regulated.

The HCBD region in myosin VI also binds several other adaptor proteins, including optineurin, NDP52 and T6BP, and K63-linked ubiquitin chains ([@bib23]; [@bib57]). Alternative splicing generates several isoforms of myosin VI. The longer isoform contains an insert N-terminal to the HCBD, which switches the binding specificity of myosin VI from adaptors such as GIPC1 to clathrin ([@bib61]). In the NMR structure of the myosin VI longer isoform (PDB ID: 2N12), a part of the insert forms a helix and packs against the HCBD. A comparison with our GIPC1-GH2/myosin VI-HCBD structure shows that the insert helix interferes with the GH2/HCBD interaction via both interfaces I and II ([Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}). These analyses refine our understanding of the structural basis for the different binding specificities between the myosin VI short and long isoforms ([@bib61]).

Mutational analyses of the interactions among PlexinD1, GIPCs and myosin VI {#s2-5}
---------------------------------------------------------------------------

We carried out pull-down experiments using GST-fusion of the myosin VI-HCBD to examine the interactions among PlexinD1, GIPC1 and myosin VI ([Figure 6](#fig6){ref-type="fig"}). As expected, GST-HCBD was able to pull-down GIPC1 but not PlexinD1~cyto~ ([Figure 6A](#fig6){ref-type="fig"}). The pull-down of GIPC1 by GST-HCBD is probably primarily mediated by interface II, which is not blocked in the autoinhibited conformation of GIPC1. Mixing the three proteins allowed GST-HCBD to pull-down both GIPC1 and PlexinD1~cyto~. Notably, the presence of Plexin~cyto~ increased the amount of GIPC1 pulled-down substantially. These results are consistent with previous observations and our structure model in which cargo binding releases the autoinhibition in GIPC1, leading to enhanced interaction with the HCBD of myosin VI ([@bib38]). We also conducted the same experiments with GIPC2 and GIPC3. The results were similar, except that the enhancement of GIPC2 binding to GST-HCBD caused by PlexinD1 is more pronounced. These results support the notion that the autoinhibited structure of GIPC1 represents a conserved regulation mechanism of the GIPC family.10.7554/eLife.27322.017Figure 6.Analyses of the interactions of myosin VI-HCBD with GIPCs and PlexinD1.(**A**) Pull-down of GIPC1, GIPC2 and GIPC3 by GST-HCBD in the absence or presence of PlexinD1~cyto~. (**B**) Effects of mutations in PlexinD1 and GIPC1 on the interactions among PlexinD1~cyto~, GIPC1 and myosin VI-HCBD. PlxD1, PlexinD1~cyto~.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.017](10.7554/eLife.27322.017)

We used the three-protein pull-down experiments to examine the interface between PlexinD1 and GIPC1 ([Figure 6B](#fig6){ref-type="fig"}). Truncation of the three C-terminal residues in the PBM of PlexinD1 (ΔSEA) virtually abolished the interaction with GIPC1. Mutating Ile1918 and Tyr1919 in PlexinD1 (I1918A/Y1919A), which occupy the hydrophobic pocket between GH1 and PDZ in GIPC1 ([Figure 4A](#fig4){ref-type="fig"}), reduced the binding to GIPC1 substantially ([Figure 6B](#fig6){ref-type="fig"}). Conversely, a mutation of Gly114 in GIPC1 (G114Y), located at the edge of the hydrophobic packet that accommodates the Ile1918/Tyr1919 motif in PlexinD1 ([Figure 4A](#fig4){ref-type="fig"}), also reduced the PlexinD1/GIPC1 interaction ([Figure 6B](#fig6){ref-type="fig"}). These results confirm that the C-terminal 'SEA' motif in PlexinD1 is essential for the binding to GIPC1, and the additional interface beyond the canonical PBM/PDZ interface also contributes the PlexinD1/GIPC interaction.

Oligomerization of the GIPC1-GH2/myosin VI-HCBD complex in solution {#s2-6}
-------------------------------------------------------------------

We examined the solution behavior of GIPC1-GH2 and the myosin VI-HCBD both alone and in complex using sedimentation velocity analytical ultracentrifugation (AUC). The GIPC1-GH2 domain at 30 μM displayed a standardized sedimentation coefficient (*s*~20,*w*~-value) of \~1.3 S, corresponding to a monomeric species of \~8 kDa ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). The *s*~20,*w*~-value of the myosin VI-HCBD (\~5 kDa) at 20 μM was 0.9 S, also consistent with a monomeric species ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). When mixed at a 1:1 molar ratio, the proteins appeared to form multiple complexes ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). We characterized these by examining the weighted-average sedimentation coefficient ($s_{20,w}^{w}$) of the entire range of species observed between 1.5 and 6 S. As the overall concentration was increased, the $s_{20,w}^{w}$ also rose, consistent with the formation of higher order species ([Figure 7A](#fig7){ref-type="fig"}). When practicable, multi-signal methods ([@bib5]) were used to confirm that both proteins participated in these complexes in an approximate 1:1 molar ratio ([Figure 7---figure supplement 1B and C](#fig7s1){ref-type="fig"}). However, we observed no species with *s*~20,*w*~-values greater than \~4.8 S ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}), and the increase in $s_{20,w}^{w}$ ceased at concentrations higher than 150 μM ([Figure 7A](#fig7){ref-type="fig"}). Based on hydrodynamic estimates, 4.8 S could represent a 5:5 complex between the GH2 and HCBD. The observation of an apparent maximum $s_{20,w}^{w}$-value was unexpected, given the potential of the open-ended GH2/HCBD complex to form infinite oligomers. One possible explanation for this phenomenon is that the formation of very long, linear polymers could be inhibited by the pressures induced by ultracentrifugation ([@bib20]; [@bib33]).10.7554/eLife.27322.018Figure 7.Oligomerization of the GIPC1-GH2/myosin VI-HCBD complex in solution.(**A**) Analytical ultracentrifugation (AUC) of the GH2, HCBD and their complexes. The dots in the top-left panel show the $s_{20,w}^{w}$-values of the wild-type GH2/HCBD complex at concentrations as indicated on the X-axis. Other panels describe the effects of mutating interfacial residues in the GH2 on the $s_{20,w}^{w}$-value of the GH2/HCBD complex (150 μM). The red and orange dashed lines indicate the *s*~20,*w*~-values of the GH2 domain at 30 μM and the HCBD at 20 μM, respectively. The black dashed line indicates the $s_{20,w}^{w}$-value of the wild-type complex at 150 μM. (**B**) AUC of the linker-GH2 and its complex with the HCBD. The top panel describes the titration analogous to the top left panel of (**A**). The bottom panel shows the effects of interfacial mutations in the linker-GH2 on the $s_{20,w}^{w}$-value of the linker-GH2/HCBD complex (150 μM). The HCBD at 150 μM sedimented as a major monomeric and minor dimeric species as shown in [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}. The s~20,*w*~-value of the monomeric species is indicated by the orange dashed lines. The s~20,*w*~-value of the linker-GH2 (red dashed line) is the same at both 38 μM and 200 μM. The black dashed line indicates the $s_{20,w}^{w}$-value of the wild-type complex at 150 μM.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.018](10.7554/eLife.27322.018)10.7554/eLife.27322.019Figure 7---figure supplement 1.AUC data of the HCBD, GH2, linker-GH2 and the complexes.(**A**) The interaction of the GIPC1-GH2 and myosin VI-HCBD studied by AUC. Shown are *c*(*s*) distributions, colored as indicated in the inset. The concentrations of the complex given represent those of the equimolar mixtures of the GH2 and HCBD. All distributions have been normalized by the respective areas under the curves. (**B**) Multi-signal sedimentation velocity (MSSV) analysis of the GH2/HCBD mixture at 30 μM. The areas under the *c~k~*(*s*) distributions represent the concentrations of the respective mixture components. The molar ratio of GH2:HCBD sedimenting faster than 1 S is 1:1. (**C**) MSSV analysis of the GH2/HCBD mixture at 150 μM. The molar ratio of GH2:HCBD in the region of 1.5--6 S is 1.1:1. (**D**) AUC analysis of the linker-GH2/HCBD titration. Data are presented in the same fashion as in (**A**). (**E**) Comparison of linker-GH2 sedimentation at low and high concentrations. (**F**) Comparison of HCBD sedimentation at low and high concentrations. Note that the experiment of the HCBD at 20 μM was conducted under low-salt conditions (150 mM NaCl), while the 150 μM sample contained 500 mM NaCl.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.019](10.7554/eLife.27322.019)10.7554/eLife.27322.020Figure 7---figure supplement 2.Salt-dependent reversible precipitation of the complex between the linker-GH2 of GIPC1 and myosin VI-HCBD.Mixing the linker-GH2 and HCBD in a buffer containing 150 mM NaCl led to precipitation. Adding NaCl to the final concentration of 500 mM re-solubilized the linker-GH2/HCBD complex.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.020](10.7554/eLife.27322.020)

We designed mutations to test the contributions of both interfaces I and II to the oligomerization. We chose to mutate the GH2 of GIPC1 because most of the residues in the myosin VI-HCBD are located in close proximity to both interfaces I and II, due to the small size of the HCBD. We made a number of GH2 mutants with single mutations in either interface I (Y275A, M276E and I278Q) or II (F319S and G323Q). The results showed that these mutations led to decreased $s_{20,w}^{w}$-values of the GH2/HCBD complex ([Figure 7A](#fig7){ref-type="fig"}), implying that the mutations disrupted oligomer formation. We combined the single mutations to generate a number of double, triple and quadruple mutants of the GIPC1-GH2 domain. The combined mutations further decreased the $s_{20,w}^{w}$-values of the complex, and in some cases virtually eliminated complex formation ([Figure 7A](#fig7){ref-type="fig"}).

We also tested the interaction of the myosin VI-HCBD with a linker-GH2 construct of GIPC1 that contains both the PDZ-GH2 linker and GH2 domain. Surprisingly, mixing the linker-GH2 and HCBD led to heavy precipitation ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). The precipitation is unlikely due to denaturation of the proteins, as it could be reversed by increasing the salt concentration from 150 mM to 500 mM. These observations, reminiscent of the reversible precipitation of IRE1 due to the high-order oligomerization ([@bib29]), suggest that the PDZ-GH2 linker promotes the polymerization of the myosin VI-HCBD/GIPC1-GH2 complex. We analyzed the linker-GH2 and its complex with the HCBD by AUC, with 500 mM salt in the buffer to prevent precipitation. The linker-GH2 protein sedimented as a monomer at both 38 μM and 200 μM, with a *s*~20,*w*~-value value of \~1.4 S ([Figure 7---figure supplement 1D and E](#fig7s1){ref-type="fig"}). The HCBD at 150 μM under the same condition sedimented predominantly as a monomer (*s*~20,*w*~-value of 0.9 S), and a minor dimer peak (*s*~20,*w*~-value of 1.6 S) ([Figure 7---figure supplements 1D](#fig7s1){ref-type="fig"} and [2F](#fig7s2){ref-type="fig"}). Similar to the GH2/HCBD complex, the average sizes of the linker-GH2/HCBD complex increased as a function of concentration, with the largest observed *s*~20,*w*~-value of \~5.5 S ([Figure 7B](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}). This value is slightly higher than that observed for the GH2/HCBD mixture at the same concentration, which could be due to the larger mass of the linker-GH2 construct and/or the formation of higher order oligomers. We introduced some double, triple and quadruple mutations as described above to the linker-GH2 construct. These mutations virtually eliminated the complex formation between the linker-GH2 and HCBD ([Figure 7B](#fig7){ref-type="fig"}).

These results together demonstrate that GIPC1-GH2 and myosin VI-HCBD form high-order oligomers in solution, and both interfaces I and II as seen in our crystal structures are required for the oligomerization. The PDZ-GH2 linker in GIPC1 appears to enhance the oligomerization, but the precise mechanism by which it does so remains unclear at present.

Oligomerization of Sema3E/PlexinD1, GIPC1 and myosin VI in cells {#s2-7}
----------------------------------------------------------------

To analyze the interactions among PlexinD1, GIPC1 and myosin VI in mammalian cells, we generated COS-7 cells stably expressing full-length mouse PlexinD1 ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). These cells were then transiently co-transfected with myosin VI and GIPC1. In these cells, a fraction of PlexinD1 was incompletely processed and remained in the ER or Golgi apparatus ([Figure 8---figure supplement 1B](#fig8s1){ref-type="fig"}). To selectively image fully processed PlexinD1 molecules, we treated the cells with the Sema3E ligand labeled with Alexa Fluor-555 and used it as a proxy for PlexinD1. Sema3E/PlexinD1, GIPC1 and myosin VI co-localized very well and formed large puncta in cells expressing wild-type PlexinD1 ([Figure 8](#fig8){ref-type="fig"}). In cells expressing PlexinD1(ΔSEA), GIPC1 and myosin VI also formed puncta together, but Sema3E did not localize to these puncta ([Figure 8](#fig8){ref-type="fig"}). There is virtually no large puncta with Sema3E/PlexinD1, GIPC1 and myosin VI co-localized in these cells. Replacing wild-type GIPC1 with the G323Q mutant, which disrupts interface II in the GH2 domain for myosin VI, also abolished formation of large puncta of co-localized Sema3E/PlexinD1, GIPC1 and myosin VI ([Figure 8](#fig8){ref-type="fig"}). These results support the notion that Sema3E, PlexinD1, GIPC1 and myosin VI can form high-order oligomers in cells, which is dependent on both the PlexinD1/GIPC1 interaction and the linear oligomerization of the GIPC1/myosin VI complex.10.7554/eLife.27322.021Figure 8.Co-localization and oligomerization of Sema3E/PlexinD1 with GIPC1 and myosin VI in mammalian cells.(**A**) Representative fluorescence images of cells. Arrow heads highlight large puncta in which Sema3E/PlexinD1 (red), GIPC1 (purple) and myosin VI (green) co-localize. Nuclei were stained with DAPI (blue). Scale bar, 5 µm. Images shown are representative from three independent samples of each group. (**B**) Quantification of puncta in each group of cells. Puncta larger than 1 µm^2^ and containing Sema3E/PlexinD1, GIPC1 and myosin VI are counted for 20 cells from each group. Each dot in the plot represents one cell. Mean and standard deviations are shown as the blue and magenta bars, respectively. p-Values are determined by two-tailed Student's t-test.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.021](10.7554/eLife.27322.021)10.7554/eLife.27322.022Figure 8---figure supplement 1.Protein expression analyses of COS-7 cells stably expressing PlexinD1.(**A**) Staining of cells with Sema3E, the ligand of PlexinD1, fused to alkaline phosphatase (See Materials and methods for details). Cell surface expression levels of PlexinD1(WT) and PlexinD1(ΔSEA), as reflected by staining darkness of cells, are similar. (**B**) Confocal image of whole cell distribution of PlexinD1(WT) as detected with anti-PlexinD1 immuno-staining. The image shows that a portion of PlexinD1 did not reach the cell surface and remained in the peri-nuclear region.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.022](10.7554/eLife.27322.022)

Discussion {#s3}
==========

Ligand-induced activation of cell surface receptors often leads to their endocytosis. The primary function of GIPCs in this process is to tether the receptors on uncoated endocytic vesicles to myosin VI, which transports the vesicles to fuse with early endosomes ([@bib27]). Our structural analyses reveal how the GIPC proteins are autoinhibited, and how they are activated upon binding of PlexinD1 or other cargos and consequently interact with myosin VI ([Figure 9](#fig9){ref-type="fig"}). The autoinhibition of both GIPCs and myosin VI ([@bib17]) helps suppress their interaction in the absence of cargo proteins, avoiding futile ATP consumption and walking of myosin VI. The linear array of the GIPC/myosin VI complex formed through their mutual bivalent binding provides an elegant mechanism for myosin VI oligomerization. PlexinD1 and many other GIPC-binding cell surface receptors undergo ligand-induced dimerization, which combined with the dimeric nature of GIPCs can potentially crosslink the GIPC/myosin VI linear oligomer into large two-dimensional assemblies ([Figure 9](#fig9){ref-type="fig"}). Such assemblies may be more efficient in performing the cellular functions of myosin VI, including clustering cargos to clathrin-coated pits, endocytic vesicle transport and maintenance of stereocilia in the inner ear. There is evidence that myosin V also forms large oligomers for processive transport ([@bib14]; [@bib30]). Oligomerization of myosin adds another instance to the increasingly prevalent higher order assemblies involved in a variety of cellular processes ([@bib62]).10.7554/eLife.27322.023Figure 9.Model of the regulated oligomerization of PlexinD1, GIPCs and myosin VI.Unbound GIPCs adopt the autoinhibited conformation (left). Binding of cargo such as PlexinD1 to GIPCs releases the autoinhibition, promoting their interaction with myosin VI and formation of the linear oligomer (right). The black dashed lines indicate that the oligomer can extend further, and multiple such oligomers can assemble into two-dimensional arrays. The transmembrane and extracellular regions of PlexinD1 are omitted for clarity.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.023](10.7554/eLife.27322.023)

The crystal structures presented here provide a framework for understanding how mutations in PlexinD1, GIPCs and myosin VI lead to diseases. Many germ-line mutations in GIPC3 and myosin VI are causatively associated with hereditary deafness ([@bib2]; [@bib3]; [@bib4]; [@bib12]; [@bib36]; [@bib45]; [@bib48]). Mapping the GIPC3 mutations to the crystal structure of apo-GIPC1 suggest that many of the mutations likely destabilize the GIPC3 protein or disrupt the interaction with myosin VI ([Table 2](#tbl2){ref-type="table"} and [Figure 10](#fig10){ref-type="fig"}). Deafness caused by these mutations is therefore likely due to loss of the anchoring function of the GIPC3/myosin VI complex in stereocilia. Dysregulation of receptor tyrosine kinases such as Vascular Endothelial Factor Receptor two and Insulin-like Growth Factor-1 Receptor can lead to cancer. GIPC-mediated endocytosis and intracellular transport are important aspects of signal regulation of these receptors ([@bib27]). Some somatic mutations in GIPCs found in human cancer ([@bib27]) also map to structural elements that are important for the protein stability or the interaction with myosin VI ([Table 2](#tbl2){ref-type="table"} and [Figure 10](#fig10){ref-type="fig"}).10.7554/eLife.27322.024Figure 10.Mapping disease-associated mutations in GIPCs to the GIPC1 structure.The structure is shown in the same view and color scheme as in the right panel of [Figure 1B](#fig1){ref-type="fig"}. The mutations listed in [Table 2](#tbl2){ref-type="table"} are mapped to the colored subunit in the dimer.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.024](10.7554/eLife.27322.024)10.7554/eLife.27322.025Table 2.Structural mapping of disease-associated mutations in GIPCs. Listed mutations are based on ([@bib3]; [@bib27]). HNSCC, head and neck squamous cell carcinoma. Mutations are mapped to GIPC1 based on the sequence alignment of GIPC1, 2 and 3 as shown in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.025](10.7554/eLife.27322.025)**GeneMutationDiseaseCorresponding residue in GIPC1Location and function of**\
**the mutated residuePossible effect of the mutation**GIPC1F319LHNSCCF319GH2,\
Interface II for myosin VIWeaken binding to myosin VIGIPC2F74YColorectal cancerF90GH1,\
Hydrophobic coreDestabilize the structureGIPC2G102EOvarian cancerG118GH1,\
Domain-swapped dimer InterfaceDestabilize the structureGIPC3M88IFamilial hearing lossM109GH1,\
Inter-domain interface with PDZDestabilize the structureGIPC3G94DFamilial hearing lossG115GH1, autoinhibitory interface with GH2,\
Part of the hydrophobic pocket accommodating the I1918/Y1919 motif in PlexinD1Disrupt the autoinhibited state,\
Weaken cargo bindingGIPC3H170NFamilial hearing lossH191PDZ,\
Key PBM binding residueWeaken cargo bindingGIPC3T221IFamilial hearing lossT242PDZ/GH2 Linker,\
Autoinhibitory interface with GH2Alter the autoinhibited stateGIPC3M255KFamilial hearing lossM276GH2,\
Autoinhibitory interface with PDZ,\
Interface I for myosin VIAlter the autoinhibited state, weaken binding to myosin VIGIPC3G256DFamilial hearing lossG277GH2,\
Autoinhibitory interface with PDZ\
Interface I for myosin VIAlter the autoinhibited state, weaken binding to myosin VIGIPC3L262RFamilial hearing lossL283GH2,\
Autoinhibitory interface with PDZ,\
Interface I for myosin VIAlter the autoinhibited state, weaken binding to myosin VI

While other plexin family members are not known to bind GIPCs ([@bib9]; [@bib19]), some of them form holo-receptors with Neuropilin 1 or 2, which contains a PBM that interacts with GIPCs ([@bib10]). In *Drosophila*, class A plexin forms a holo-receptor with the receptor guanylyl cyclase Gyc76C, which binds GIPC1 and facilitates plexin-mediated motor axon guidance ([@bib11]). GIPCs therefore can use diverse mechanisms to regulate plexin signaling. Intriguingly, the PBM of PlexinD1 is in principle available for binding GIPCs constitutively, raising the question whether and how the plexin/GIPC interaction is regulated. One potential mechanism for regulating the interaction in PlexinD1 may be phosphorylation of conserved Tyr1919 and Ser1923, which would likely prevent GIPC binding based on the PlexinD1/GIPC1 complex structure. Interestingly, the sequence context of Tyr1919 resembles the consensus phosphorylation site for the Src family kinases ([@bib19]). Future studies will determine the potential role of PlexinD1 phosphorylation on the formation of the PlexinD1/GIPC1 complex.

Materials and methods {#s4}
=====================

Protein expression and purification {#s4-1}
-----------------------------------

The coding regions for mouse PlexinD1~cyto~ with (residues 1297--1925) and without the JM-segment (residues 1339--1925), mouse GIPC1 GH1-PDZ-GH2 version 1 (residues 52--333), GIPC1 GH1-PDZ-GH2 version 2 (residues 52--327), GIPC1 linker-GH2 (residues 217--333), GIPC1 GH2 (residues 258--333), mouse GIPC2 GH1-PDZ-GH2 (residues 40--314), GIPC2 GH2 (residues 238--314) and mouse GIPC3 GH1-PDZ-GH2 (residues 20--307) were sub-cloned into a modified pET-28a vector (Novagen). Mutations were introduced by polymerase chain reaction-based mutagenesis. Proteins expressed using these constructs contain an N-terminal His~6~-tag and human rhinovirus 3C protease cleavage site. Proteins were overexpressed in the bacterial strain BL21(DE3) and purified by Ni^2+^ ion affinity chromatography. The His~6~-tag was removed by treatment with the 3C protease. Proteins were further purified using ion-exchange and gel filtration chromatography. The GH1-PDZ-GH2 domains of GIPC1 showed two peaks on gel filtration chromatography, presumably corresponding to the dimer and monomer, respectively. The monomeric proteins were unstable and precipitated when concentrated. The dimeric proteins were collected and concentrated for subsequent experiments. GIPC2 and GIPC3 both ran as a single peak corresponding to the dimer species. The coding region for the HCBD of mouse myosin VI (residues 1052--1096; residues numbers based on the short version myosin VI, GeneBank number BC144917) was inserted into the pGEX-6p-1 vector (GE healthcare, Pittsburgh, PA). The GST-HCBD fusion protein was overexpressed in BL21(DE3) and purified using glutathione affinity chromatography followed by gel filtration. To produce the HCBD of myosin VI without the GST moiety, the fusion protein was treated with the 3C protease and GST was removed by passing through a glutathione affinity column. All the proteins were concentrated using Amicon concentrators (Millipore, Billerica, MA) and stored at −80°C before use.

The coding region for mouse Sema3E (residues 1--678) with a C-terminal His~8~-tag was cloned into the pEZT-BM vector and expressed as a secreted protein in HEK293S-GnTI^−^ cells (ATCC, catalogue \#CRL-3022; not independently authenticated) by using the BacMam system ([@bib37]). The protein was captured by using Ni^2+^-NTA beads from the culture medium and further purified by gel filtration chromatography. Sema3E was labeled with Alexa Fluor-555 (Invitrogen, Waltham, MA) according to the manufacture's instruction. Briefly, Sema3E in phosphate buffered saline (PBS) at 10 mg/ml was incubated with amine-reactive Alexa Fluor-555 for 1 hr at room temperature. Sema3E conjugated with Alexa Fluor-555 was purified by gel filtration chromatography, concentrated and stored at −80°C. Alkaline phosphatase-tagged Sema3E (AP-Sema3E) was expressed in transiently transfected HEK293T cells (ATCC, Manassas, VA, catalogue \#CRL-3216; not independently authenticated) as described previously ([@bib22]).

Crystallization and structure determination {#s4-2}
-------------------------------------------

Initial crystallization trials were carried out in 96-well plates using the sitting-drop vapor diffusion method at 20°C. Crystallization conditions were optimized in 24-well plates using the hanging-drop vapor diffusion method. For crystallizing the PlexinD1~cyto~/GIPC1, GIPC1-GH2/myosin VI-HCBD and GIPC2-GH2/myosin VI-HCBD complexes, the interacting proteins were mixed at an equimolar ratio and subjected to crystallization screens directly. The optimized crystallization condition for PlexinD1 (residues 1333--1925, 10 mg/ml) included 0.1 M imidazole (pH 7.8) and 15% (w/v) PEG8000. The condition for GIPC1 (residues 52--327, 5 mg/ml) included 0.2 M Li~2~SO~4~, 0.1 M HEPES pH 7.5 and 25% (w/v) PEG3350. The condition for the complex (5 mg/ml) between PlexinD1 and GIPC1 (residues 52--333) was 0.1 M Bis-Tris pH 5.5 and 2 M (NH~4~)~2~SO~4~. The condition for the GIPC1-GH2(258--333)/myosin VI-HCBD(1052--1094) complex (15 mg/ml) was 0.1 M Bis-Tris pH 6.0 and 2 M (NH~4~)~2~SO~4~. The condition for the GIPC2-GH2(238--314)/myosin VI-HCBD(1052--1094) complex (15 mg/ml) was 0.1 M MES pH 6.5% and 10% (w/v) PEG20000. Crystals were cryo-protected in the crystallization buffers supplemented with 20% (v/v) ethylene glycol or glycerol, and flash-cooled in liquid nitrogen before data collection. Diffraction data were collected at 100 K on beamline 19ID at the Advanced Photon Sources (Argonne National Laboratory, Argonne, IL). The data were processed by using the HKL2000 software package ([@bib40]).

All the structures were solved by molecular replacement (MR) using Phaser in the Phenix software package ([@bib1]; [@bib35]). The structure of PlexinD1~cyto~ was solved using the PlexinA3~cyto~ structure (PDB ID: 3IG3) with the JM-segment removed as the search model. The PlexinD1~cyto~ structure was then used as the search model to obtain the initial phases for the PlexinD1~cyto~/GIPC1 complex structure, which generated an electron-density map that showed clear features of the PDZ domain. The PDZ domain of GIPC2 (PDB ID: 3GGE) was manually placed into the density map using the program Coot ([@bib15]). Subsequent iterative model building and refinement using Phenix and Coot, respectively, allowed the GH1 domain of GIPC1 to be built and refined. While the GH2 domain was present in the protein used for crystallization, it was completely disordered and invisible in the electron-density map.

The individual GH1 and PDZ domains from the PlexinD1~cyto~/GIPC1 complex structure were used as the search models to solve the structure of apo-GIPC1. The initial electron-density map showed weak features of the GH2 domain, which were improved through iterative manual model building in Coot, automatic building using the Autobuild module and refinement with the Refine module in Phenix. Despite the high resolution (1.9 Å), the R~free~ remained above 30% after many rounds of refinement. Analyses of the diffraction data with the Xtriage module in Phenix suggested that the diffraction data were twinned with the twin operator of (h, -k, -l). Refinement with the twin operator applied in Phenix led to the final model with R~free~of \~ 17.5%. The refined twin fraction is \~33%. The GH2 domain from the refined apo-GIPC1 structure was then used as the search model to solve the structures of HCBD of myosin VI in complex with GIPC1-GH2 and GIPC2-GH2, respectively. For both structures, the electron-density maps calculated from the five protomers of GH2 in the asymmetric units were clear enough to allow the HCBD of myosin VI to be modeled via manual building in Coot and Autobuild in Phenix.

Data collection and refinement statistics are listed in the [Table 1](#tbl1){ref-type="table"}. Model quality was checked by using MolProbity ([@bib13]). The structure figures were generated in Pymol (<http://www.pymol.org/>).

Pull-down assays with purified proteins {#s4-3}
---------------------------------------

The GST fusion protein of HCBD of myosin VI was incubated with GIPC1, GIPC2 or GIPC3 in the absence or presence of PlexinD1~cyto~(with JM) in the pull-down buffer containing 10 mM Tris (pH 8.0), 150 mM NaCl and 1 mM DTT at room temperature for 30 min before the pull-down experiments. The concentrations of the individual proteins in the initial 20 μl mix were all at 1 μM. The same conditions were used for incubating the mutants. To perform the pull-down experiments, 20 μl washed glutathione beads were added and incubated for an additional 30 min at room temperature. Beads were pelleted and washed with 1 ml of the pull-down buffer three times. Proteins remaining on the beads were extracted with standard SDS-PAGE loading buffer containing 1% (w/v) SDS, resolved in SDS-PAGE and stained with Coomassie blue R250.

Analytical ultracentrifugation {#s4-4}
------------------------------

For ultracentrifugation experiments of the GH2-C-terminal protein of GIPC1 (residues 258--333) and its complex with the HCBD of myosin VI, the centrifugation buffer contained 10 mM Tris (pH 8.0), 150 mM NaCl and 1 mM TCEP. The complex between the linker-GH2-C-terminal protein and HCBD precipitated heavily in this buffer. Therefore, for the ultracentrifugation experiments with linker-GH2-C-terminal, the concentration of NaCl in the buffer was increased to 500 mM. The individual proteins and protein complexes (at 1:1 molar ratio) at various concentrations were prepared and incubated overnight at 20°C. The samples (\~400 μl) were loaded into the 'sample' side of dual-sectored charcoal-filled Epon centerpieces, while the 'reference' sectors were loaded with the centrifugation buffer of the same volume. Filled cells were loaded into a An50Ti rotor and equilibrated for 2 hr under vacuum in a Beckman Coulter Optima XL-I ultracentrifuge at 4°C prior to centrifugation. Data were acquired at 50,000 rpm at 4°C via absorbance at 305 nm and interference optics. Data were analyzed using the *c(s)* methodology in the program SEDFIT ([@bib47]). Multi-signal analyses were carried out in SEDPHAT ([@bib5]). All figures featuring *c(s)* distributions were rendered with the program GUSSI ([@bib7]).

Fluorescence imaging of cells {#s4-5}
-----------------------------

The cDNAs of full-length mouse PlexinD1(WT) and PlexinD1(ΔSEA) were inserted into the Lentiviral vector pTY with the Elongation Factor 1a (EF1a) promoter (Clontech, Mountain View, CA). The constructs were transfected into HEK293T cells to generate Lentiviruses, which were used to infect COS-7 cells (ATCC, catalogue \#CRL-1651). Cells were not independently authenticated, but checked by 4,6-Diamidino-2-phenylindole (DAPI) staining to ensure no microplasma contamination. Cells were cultured in DMEM medium (Invitrogen) supplemented with 1% (V/V) penicillin/streptomycin and 10% (V/V) FBS with 5% CO~2~ at 37°C. Blasticidin (10 µg/ml) was used to select for infected COS-7 cells stably expressing either PlexinD1(WT) or PlexinD1(ΔSEA). Cell surface expression of the PlexinD1 proteins was confirmed by staining with AP-Sema3E (2 nM) as described previously ([@bib22]), except that Sema3E treatment was conducted on ice for 15 min to prevent cell collapse and endocytosis. Whole cell distribution of PlexinD1 was detected by immune-staining with an anti-PlexinD1 antibody (Abcam, San Francisco, CA, catalogue \#ab96313) and an Alexa-555-labeled goat anti-rabbit secondary antibody (Invitrogen, catalogue \#A-21428). Cells were imaged with a 40X objective and a CCD camera mounted on a Nikon A1R confocal microscope. The excitation and emission wavelengths were 555 nm and 572 nm, respectively.

To analyze the co-localization of Plexin D1 with GIPC1 and myosin VI, human myosin VI short version (GeneBank number U90236.2) was inserted into pEGFP-C3 (Clontech) for expression of N-terminal GFP-fused myosin VI. GIPC1 wild-type and the G323Q mutant were cloned into pcDNA3.1 (Invitrogen) with a C-terminal HA-tag. The myosin VI plasmid was co-transfected with the GIPC1 wild-type or the G323Q mutant plasmid with Fugene 6 (Promega, Fitchburg, WI) into the PlexinD1-expressing COS-7 cells described above. Twenty-four hours after transfection, cells were treated with 15 nM Alexa Fluor-555-labelled Sema3E for 12 min at 37°C. Cells were permeabilized with 0.05% (w/v) saponin for 10 min and non-specific binding sites were blocked by Quenching buffer (0.01% (w/v) saponin, 2% (w/v) BSA, 0.1% (w/v) lysine in PBS, pH7.4) for 30 min. HA-tagged GIPC1 was stained with a chicken anti-HA antibody (Novus, Littleton, CO, catalogue \#NB600-361) and an Alexa Fluor 647-labelled goat anti-chicken antibody (Invitrogen, catalogue \#1806124). Cells were imaged with a 60 × 1.4 numerical aperture objective and a CCD camera mounted on a Nikon A1R confocal microscope. Z-stacks were obtained and collapsed into 2D images. Excitation wavelengths used were 405 nm (for DAPI), 488 nm (for GFP-myosin VI), 555 nm (for Alexa Fluor-555 labeled Sema3E) and 647 nm (for GIPC1 stained with Alexa Fluor-647-labeled antibody). The corresponding emission wavelengths were 421 nm, 519 nm, 572 nm and 665 nm, respectively.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Structure analyses reveal a regulated oligomerization mechanism of the PlexinD1/GIPC/myosin VI complex\" for consideration by *eLife*. Your article has been favorably evaluated by Philip Cole (Senior Editor) and three reviewers, one of whom, Suzanne Pfeffer (Reviewer \#1), is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

GIPCs comprise a family of adaptor proteins that link semaphorin signalling via plexin receptors to cellular transport via myosin VI motors. Previous work has elucidated structures of the cytosolic portions of plexins, but the molecular mechanisms how GIPCs couple plexin receptors with myosin motors have remained enigmatic. Here, Shang et al. present a comprehensive structural analysis revealing the molecular mechanisms of GIPC auto-inhibition and activation. In particular, they report the first full length crystal structure of a GIPC showing a domain swapped dimer that is auto-inhibited by intra- and intermolecular interactions. The structure of GIPC bound to a cytosolic plexinD1 fragment reveals the mechanism how auto-inhibitory restraints in GIPC are released. Furthermore, the structure of the GIPC-GH2 domain in complex with a helical fragment of myosin VI uncovers an unexpected mechanism how GIPC clusters myosin VI motors. The structural work is supported by some rather basic biochemical and cell-based experiments. The current manuscript describes a spectacular, high quality structural analysis that could easily be included in several publications. The structure-based functional analyses are not as exhaustive as the structural work, but essentially confirm the main implications of the structures.

1\) The reviewers agree that the text can be improved.

2\) The authors must show a gel to determine if degradation has taken place in the crystals (subsection "Structure of the PlexinD1/GIPC1 complex", second paragraph).

3\) General electron density must be shown throughout (probably in supplementary information).

4\) And quantitation of the micrographs is required.

*Reviewer \#1:*

1\) Subsection "Structure of the PlexinD1/GIPC1 complex", second paragraph. It should not be hard to rule out \"degradation\" in the crystal to make this conclusion stronger. Please check this by running a gel.

2\) The light microscopy needs quantitation -- number of puncta per cell, number cells counted. If staining is diffuse (not diffused) that can also be represented as overall fluorescence intensity per micron squared or other metric.

3\) The Introduction is clearly written but please improve the discussion to explain the order of events that might lead to MyoVI recruitment. (1, ligand binding, dimerization etc.). Explain the events that would uninhibit GIPC1 etc. Propose models for how this might work, to guide next experiments. At the end of the Introduction, please spell out explicitly which partial structures were already determined and how this study builds on those structures. While mentioned in the text, this will help the reader better appreciate how this work builds on previous work of others.

4\) There are a large number of acronyms used throughout the text -- where possible, please refer to domains by including the protein from which they derive. Otherwise the text is very challenging for those not studying these particular proteins. Example, the first sentence of the subsection "Interactions in the two interfaces between the GH2 and HCBD domains" should read GIPC1 GH2 with MyoVI HCBD; subsection "Structure and oligomerization of the GH2/myosin VI complex", first paragraph -- at least refer to \"HCBD\" so the reader knows where to look. If possible, add name of protein above bars in [Figures 1](#fig1){ref-type="fig"}--[3](#fig3){ref-type="fig"} to help the reader.

5\) Saponin is not saponine.

*Reviewer \#2:*

1\) One claim in the Abstract and the work, that I worry about is that whilst a domain swapped dimer is undoubtedly present, whether the inhibition is in trans or cis is dependent on modelling of a linker segment invisible in the electron density and therefore I would say precarious. The manuscript certainly needs to point this out and show this and I think present the other obvious possibility i.e. be fairer to an alternative model, which does not detract from the work nor its meaning or \'publishability \'in *eLife*.

2\) Subsection "Structure of GIPC1 in the dimeric and autoinhibited state", third paragraph -- inhibition in trans. I think one suggestion of a distance as determining whether inhibition is cis or trans is not acceptable. The linker could go 50Å or so if fully extended so both the 20Å and 40Å possibilities work. I don\'t think it matters for the impact of the paper or the biology which is true in vivo, or indeed if it is the same as the situation in the crystal but I feel it should be pointed out as a possibility. It would be good to show some support for the model. The phrase \"autoinhibited conformation that hinders binding to both PBM-containing cargo proteins and myo6\" should be supported with experimental data -- pull downs to show weaker binding would be obvious and would improve this section greatly -- or soften the text.

3\) Subsection "Structure of the PlexinD1/GIPC1 complex", third paragraph. Again, the phrase \"supporting the notion that...\" is not really acceptable. Showing the competition should be relatively trivial in a pull-down experiment and this could and should be done I think.

4\) Subsection "Structure of the PlexinD1/GIPC1 complex", last paragraph. [Figure 2C](#fig2){ref-type="fig"} panels are very small and cluttered and difficult to understand. Please make bigger and/or simpler.

5\) Subsection "Structure and oligomerization of the GH2/myosin VI complex", second paragraph. Why do the authors believe that myo6 and GIPC polymerisation is needed to cluster receptors in CCPs in initial stages of CME? Which receptors? Clathrin and its associated adapters, mainly AP2, do this efficiently in vivo and in vitro so why the need to invoke myo6/GIPC in it and in any case this would only work for a very small subset of receptors. I also fail to see how this tallies with quantitative mass spec data such as Borner and Robinson showing that there is hardly any of either GIPC and myo6 in CCPs/CCVs. The long-distance runs of endocytic vesicles over actin presumably occur after CCV uncoating and the clathrin/adapter coat would block this interaction with large actin filaments. I think that this whole section of the model needs rethinking and rewriting.

*Reviewer \#3:*

[Figure 4](#fig4){ref-type="fig"} should be quantified from 2-3 repetitions, some quantification of the co-localization in [Figure 6](#fig6){ref-type="fig"} would also be desirable.

[Figure 5](#fig5){ref-type="fig"}, dashed lines for GH2, HCBD, linker GH2: If I understand correctly, these lines are based on a single measurement at a low protein concentration (30 µM for GH2, 20 µM for HCBD)? It would be important to determine additional sedimentation values for the isolated GH2, HCBD and linker GH2 domains at the same high protein concentrations as used for the complex to confirm that these proteins do not aggregate on their own at high protein concentrations.

[Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}. I am not an AUC expert, but I found the normalization of the traces to the highest value quite confusing. Why not normalize the traces to the total area under the curves for a better comparison of the fraction size of each peak? When looking at the majority of the traces, discrete s20 species are apparent. Can these be assigned to monomers, dimers, trimers, tetramers and pentamers? Is the weighted average sedimentation coefficient really the best means to analyze AUC runs with such distinct species?

[Figure 6](#fig6){ref-type="fig"}: \'In these cells, a fraction of PlexinD1 was incompletely processed and remained in the ER or Golgi apparatus.\' What is this assumption based on? Please provide the data.

Generally: I find it important if the method of structure solution (e.g. molecular replacement with what?), the diffraction limit of the crystals and the R~work~/R~free~ are shortly mentioned for every structure referred to in the manuscript to immediately provide a measure of the quality of the structure, without having to refer to the data collection table.

[Figure 1](#fig1){ref-type="fig"}: The GIPC structure has several completely new features that should be more thoroughly described and analysed. Please enlarge the figures as much as possible that details can be better recognized. Please provide a topology plot (with all secondary structure elements labelled) of the dimeric GIPC structure to better understand the domain architecture, organization and the domain swap of GIPC. In the supplement, please provide structural comparisons of the GH1 and GH2 domains to related domains in other proteins (e.g. ubiquitin, etc.) to better describe their structural relationships. Also, a one sentence description of the PDZ domain architecture should be included in the text. In the close-ups, please label the indicated residues and indicate more secondary structure element, N and C-termini and use colors that have contrast (for example, a light green secondary structure on a yellow surface is not suited). In printouts, it is generally difficult to recognize much below semi-transparent surfaces, especially in small figures as those in the manuscript. Why not use a proper surface representation with some more contrast and provide additional figures to specifically show residues involved in intra- and intermolecular interactions (ideally with a minimum of additional secondary structure elements in the background -- better remove it instead of fading it out). Include properly labelled surface conservation plots of the domains to better visualize which contact areas are conserved and which are not.

Discuss the domain swap: Would a monomeric GIPC be stable or would the removal of one monomer lead to a collapse of the GH1 domain? Is there a structural possibility to envisage a monomeric GIPC, e.g. one without domain swap, for example, when the polypeptide chain is newly synthesized?

[Figure 2](#fig2){ref-type="fig"}. Although the structure of the plexin cytoplasmic domain has been described before, it still would be helpful for the casual reader to properly describe the domain architectures of the crystallized constructs here. For example, mention that the GAP domain is constituted from C1 and C2 and has a fold related to RasGAPs. Describe in more detail which structures of plexins have been determined before and how do they compare to the current structure. Add \'mouse PlexinD1\' in [Figure 2A](#fig2){ref-type="fig"}, indicate the boundaries of the crystallized construct below, indicate in [Figure 2B](#fig2){ref-type="fig"} which structure is the apo and which the GIPC-bound form (the figure should be self-explanatory without reading the legend). Use separate colors for the C1, RBD, C2 domains, indicate the binding sites for small GTPases (are they accessible in these structures for small G protein binding?), indicate N- and C-termini of the construct. Label the tail segments. In the close-ups of [Figure 2C](#fig2){ref-type="fig"}, it is hard to recognize anything, the interacting residues in the GH1 and PDZ domain are almost invisible: Remove any non-essential detail (for example, the electron densities in the left figures), better concentrate on visualizing the contacts instead. Indicate relevant additional secondary structure elements, show surface conservation plots in the supplement to visualize whether interacting residues are conserved in plexins and GIPCs. Properly label [Figure 2F](#fig2){ref-type="fig"} to indicate which constructs have been superimposed.

From an aesthetical point of view: The secondary structure representations in the [Figure 2C](#fig2){ref-type="fig"} close-up look ugly: The two helices of the PlxD1 on the left should be separated by a short loop, and the two strands of the PDZ domain look twisted and weird. Manually re-assign secondary structure elements in pymol and chose another, higher quality strand representation in pymol.

[Figure 3](#fig3){ref-type="fig"}: I would recommend to first describe the two assembly interfaces in detail in the text and then refer to the higher order assembly, it is rather confusing and counter-intuitive as it is now. Again, the involved amino acids are difficult to recognize in the semi-transparent surface representation in [Figure 3B](#fig3){ref-type="fig"} -- either remove the surface or provide two separate figures.

Please provide superpositions of all five GH2-HCBD complex in the ASU in the supplement (including the complex that links the two ASUs). Are they really completely identical? Any structure-based hypothesis why oligomerization in AUC stops at the tetramer/pentamer level? For example, would a related closed tetrameric/pentameric assembly be possible (with some minor reorientation of the assembly sites)?

It is distracting that the mutagenesis data appear at the end of the results, whereas the residues participating in the assembly are described much earlier. The authors may consider including the mutagenesis/AUC data immediately after describing the relevant structural data. For example, some AUC data of [Figure 5](#fig5){ref-type="fig"} would neatly fit below [Figure 3](#fig3){ref-type="fig"}. [Figure 4](#fig4){ref-type="fig"}, [Figure 6](#fig6){ref-type="fig"} and some AUC data from [Figure 5](#fig5){ref-type="fig"} may be merged in one coherent figure describing the assembly of the Plexin-GIPC-myosin complex.

[Figure 5](#fig5){ref-type="fig"} bottom: Please provide the exact amino acid exchanges of all mutants (numbers) in the figure, not in the legend.

[Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}: Very nice figure, but difficult to recognize on a black background. Why not chose different colors for neighboring ASUs (at least for the colored filament) to better visualize how the continuous filament is formed by adjacent ASUs.

[Figure 7](#fig7){ref-type="fig"}: Please label the individual domains of GIPC in the figure (ideally with the corresponding domain colors). Discuss: How do the GIPC-PlxD1 hetero-tetramers relate to the GIPC-myosin oligomer? Do the authors envisage a further 3D cross-linking by the combination of tetramers and oligomers or could the tetramers assemble along the oligomeric GIPC-myosin filament?

[Table 1](#tbl1){ref-type="table"}: Please indicate in addition the contents of the ASU, e.g. 1 dimeric GIPC complex, 2 GIPC/plexin dimers, etc.

[Table 2](#tbl2){ref-type="table"}: Please provide an additional main figure showing the site of disease-related mutations in the auto-inhibited or liganded GIPC structure and discuss the implications in more detail. This information is most relevant for many medical researchers.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Structure analyses reveal a regulated oligomerization mechanism of the PlexinD1/GIPC/myosin VI complex\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Philip Cole as the Senior Editor, and Suzanne Prefer as the Reviewing Editor, and is essentially ready to be accepted by *eLife*.

Regarding the text in response to Comment 5 of reviewer \#2: for greater precision, we request the following edit to the text, \"Previous studies have suggested that GIPC1 and myosin VI contribute to clustering of cell surface receptors into clathrin-coated pits at the initial stage of endocytosis IN CERTAIN CELL TYPES, particularly those with microvilli (Hasson, 2003). In such cells, high-order oligomerization of GIPC1 and myosin VI may make this process more efficient.\"

10.7554/eLife.27322.038

Author response

1\) The reviewers agree that the text can be improved.

We have made many changes to the text and figures as suggested by the reviewers to enhance the presentation of the work.

2\) The authors must show a gel to determine if degradation has taken place in the crystals (subsection "Structure of the PlexinD1/GIPC1 complex", second paragraph).

As suggested, we have re-grown crystals of the PlexinD1/GIPC1 complex. A large number of crystals were collected, washed in the crystallization buffer and analyzed on SDS-PAGE. The result is now shown as [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}, demonstrating that the crystals contain intact PlexinD1 and GIPC1. There are a few weak bands besides the strong bands of intact PlexinD1 and GIPC1. These are likely small amounts of impurity or partially degraded proteins, which precipitated during the 3-day incubation in the crystallization drops at room temperature and stuck to crystal surface or "crystallization drop skin" that couldn't be washed away before the gel analysis. We have added the following sentence to the text "A gel analysis shows that the GIPC1 protein is intact in crystals ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}), suggesting that the linker-GH2 domains are present but completely disordered in the PlexinD1/GIPC1 complex structure."

3\) General electron density must be shown throughout (probably in supplementary information).

We have included one figure of electron density map for a key part of each structure reported in the paper. We do not show electron density for the entire structures because it becomes highly cluttered and difficult to interpret. The structure factors and coordinates for all the structures reported in the manuscript have been deposited into the PDB database, and will be released as soon as the paper is accepted. The quality of the structures can be checked thoroughly by interested readers.

*4) And quantitation of the micrographs is required.*

This has been done and included in [Figure 8](#fig8){ref-type="fig"} in the revised manuscript. We counted puncta with Sema3E/PlexinD1, myosin VI and GIPC1 co-localized and area larger than 1 µm^2^ in each group.

*Reviewer \#1:*

*1) Subsection "Structure of the PlexinD1/GIPC1 complex", second paragraph. It should not be hard to rule out \"degradation\" in the crystal to make this conclusion stronger. Please check this by running a gel.*

See the answer to major point 2 above.

*2) The light microscopy needs quantitation -- number of puncta per cell, number cells counted. If staining is diffuse (not diffused) that can also be represented as overall fluorescence intensity per micron squared or other metric.*

See the answer to major point 2 above. We realized that the description regarding "diffuse" is vague and difficult to quantify, and decided to use the number of puncta with area larger than 1 µm^2^ as a simple metric for comparing the different groups regarding their ability to form large oligomers in cells. The descriptions regarding "diffuse" are removed.

*3) The Introduction is clearly written but please improve the discussion to explain the order of events that might lead to MyoVI recruitment. (1, ligand binding, dimerization etc.). Explain the events that would uninhibit GIPC1 etc. Propose models for how this might work, to guide next experiments. At the end of the Introduction, please spell out explicitly which partial structures were already determined and how this study builds on those structures. While mentioned in the text, this will help the reader better appreciate how this work builds on previous work of others.*

These are excellent suggestions. We have added the following sentences to the beginning of the last paragraph in the Introduction "Structures of plexins, the PDZ domain of GIPC2 (PDB ID: 3GGE) and the GIPC-binding region in myosin VI have been reported previously (Bell et al., 2011; He et al., 2016; He et al., 2009; Tong et al., 2009; Wang et al., 2013; Wang et al., 2012; Wollscheid et al., 2016). However, structures of full-length GIPCs and their complexes with either cargos or myosin VI are not available, hindering our understanding of the mechanisms underlying GIPC functions."

And the following sentences to the beginning of the Discussion: "Ligand-induced activation of cell surface receptors often leads to their endocytosis. The primary function of GIPCs in this process is to tether the receptors on uncoated endocytic vesicles to myosin VI, which transports the vesicles to fuse with early endosomes (Katoh, 2013)."

*4) There are a large number of acronyms used throughout the text -- where possible, please refer to domains by including the protein from which they derive. Otherwise the text is very challenging for those not studying these particular proteins. Example, the first sentence of the subsection "Interactions in the two interfaces between the GH2 and HCBD domains" should read GIPC1 GH2 with MyoVI HCBD; subsection "Structure and oligomerization of the GH2/myosin VI complex", first paragraph -- at least refer to \"HCBD\" so the reader knows where to look. If possible, add name of protein above bars in [Figures 1](#fig1){ref-type="fig"}--[3](#fig3){ref-type="fig"} to help the reader.*

Done as suggested.

*5) Saponin is not saponine.*

Corrected.

*Reviewer \#2:*

*1) One claim in the Abstract and the work, that I worry about is that whilst a domain swapped dimer is undoubtedly present, whether the inhibition is in trans or cis is dependent on modelling of a linker segment invisible in the electron density and therefore I would say precarious. The manuscript certainly needs to point this out and show this and I think present the other obvious possibility i.e. be fairer to an alternative model, which does not detract from the work nor its meaning or \'publishability \'in eLife.*

We agree and have modified the text to make it more clear that the alternative connection is possible: "The alternative connection is less likely but possible, as the gap of \~40 Å in this configuration can be spanned by the 17-residue disordered linker region."

*2) Subsection "Structure of GIPC1 in the dimeric and autoinhibited state", third paragraph -- inhibition in trans. I think one suggestion of a distance as determining whether inhibition is cis or trans is not acceptable. The linker could go 50Å or so if fully extended so both the 20Å and 40Å possibilities work. I don\'t think it matters for the impact of the paper or the biology which is true in vivo, or indeed if it is the same as the situation in the crystal but I feel it should be pointed out as a possibility. It would be good to show some support for the model. The phrase \"autoinhibited conformation that hinders binding to both PBM-containing cargo proteins and myo6\" should be supported with experimental data -- pull downs to show weaker binding would be obvious and would improve this section greatly -- or soften the text.*

We have modified the text to clearly point out the alternative possibility. Regarding the autoinhibition, the results in [Figure 4](#fig4){ref-type="fig"} ([Figure 6](#fig6){ref-type="fig"} in the revised manuscript) address this question. The bindings between myosin VI and GIPCs are weak, but they are enhanced in the presence of PlexinD1. These results support the notion that PlexinD1 competes with GH2 for binding to the PDZ domain, leading to dislodge of GH2 and enhanced interaction with myosin VI.

*3) Subsection "Structure of the PlexinD1/GIPC1 complex", third paragraph. Again, the phrase \"supporting the notion that...\" is not really acceptable. Showing the competition should be relatively trivial in a pull-down experiment and this could and should be done I think.*

See answer to point 2, the results in [Figure 4](#fig4){ref-type="fig"} ([Figure 6](#fig6){ref-type="fig"} in the revised manuscript) address this concern.

*4) Subsection "Structure of the PlexinD1/GIPC1 complex", last paragraph. [Figure 2C](#fig2){ref-type="fig"} panels are very small and cluttered and difficult to understand. Please make bigger and/or simpler.*

We agree and have split the original [Figure 2](#fig2){ref-type="fig"} into two figures. [Figure 2C](#fig2){ref-type="fig"} is now enlarged and shown together with 2E and 2F in new [Figure 4](#fig4){ref-type="fig"}.

*5) Subsection "Structure and oligomerization of the GH2/myosin VI complex", second paragraph. Why do the authors believe that myo6 and GIPC polymerisation is needed to cluster receptors in CCPs in initial stages of CME? Which receptors? Clathrin and its associated adapters, mainly AP2, do this efficiently* in vivo *and in vitro so why the need to invoke myo6/GIPC in it and in any case this would only work for a very small subset of receptors. I also fail to see how this tallies with quantitative mass spec data such as Borner and Robinson showing that there is hardly any of either GIPC and myo6 in CCPs/CCVs. The long-distance runs of endocytic vesicles over actin presumably occur after CCV uncoating and the clathrin/adapter coat would block this interaction with large actin filaments. I think that this whole section of the model needs rethinking and rewriting.*

The review article (Hasson, 2003, cited in the sentence in question) discussed this less well known function of GIPC1 and myosin VI, particularly in microvili of polarized cells. This review article cites a number of papers suggesting this function, in addition to the better-known role of GIPC and myosin VI in transport of uncoated vesicles. We have modified the sentence to make this point more clear. "Previous studies have suggested that GIPC1 and myosin VI contribute to clustering of cell surface receptors into clathrin-coated pits at the initial stage of endocytosis (Hasson, 2003). The high-order oligomerization of GIPC1 and myosin VI may make this process more efficient."

*Reviewer \#3:*

*[Figure 4](#fig4){ref-type="fig"} should be quantified from 2-3 repetitions, some quantification of the co-localization in [Figure 6](#fig6){ref-type="fig"} would also be desirable.*

Quantification of [Figure 6](#fig6){ref-type="fig"} is now included in (new [Figure 8](#fig8){ref-type="fig"}). We prefer not to quantify gels, as they show large variation despite that the results are qualitatively robust and reproducible. [Author response image 1](#fig11){ref-type="fig"} shows some of the repeats we have done on GIPC1 (A) and GIPC2 (B). Note the G98Y mutant of GIPC2 is equivalent to G114Y of GIPC1. In addition, we did similar experiments using zebra fish GIPC1 and PlexinD1 (C). We tested the two constructs of zebra fish PlexinD1, zfPlxD1152end (with the juxtamembrane segment) and zfPlxD1194end (without the juxtamembrane segment). All the results are similar to those showing in [Figure 4](#fig4){ref-type="fig"} in the original manuscript ([Figure 6](#fig6){ref-type="fig"} in the revised manuscript), with PlexinD1 enhancing the interaction between myosin VI and GIPC.10.7554/eLife.27322.026Author response image 1.**DOI:** [http://dx.doi.org/10.7554/eLife.27322.026](10.7554/eLife.27322.026)

*[Figure 5](#fig5){ref-type="fig"}, dashed lines for GH2, HCBD, linker GH2: If I understand correctly, these lines are based on a single measurement at a low protein concentration (30 µM for GH2, 20 µM for HCBD)? It would be important to determine additional sedimentation values for the isolated GH2, HCBD and linker GH2 domains at the same high protein concentrations as used for the complex to confirm that these proteins do not aggregate on their own at high protein concentrations.*

We appreciate the reviewer's careful examination of this issue, which helped us discover some errors in the figure and improve our data analyses. In original [Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}, the HCBD concentration was labeled "20 µM", which actually should be 150 µM. Therefore, we actually did do experiments on the HCBD at both low and high concentrations, with the caveat that they were conducted at low-salt (150 mM) and high-salt (500 mM) concentrations respectively. In addition, we found that our initial analyses of the data from the HCBD experiments had some errors, which led to our conclusion as stated in the text "The s~20,w~-value of the HCBD (\~5 kDa) at 20 μm was difficult to discern...". We have corrected the errors by re-doing the analyses, and compared the results for the HCBD at both the low and high concentrations (new [Figure 7---figure supplement 1F](#fig7s1){ref-type="fig"}). At the low concentration, the HCBD is a monomer (s~20,w~-value of 0.9). At the high concentration, the HCBD sedimented predominantly as a monomer, but also showed a minor dimeric species (s~20,w~-value of 1.6). There is no obvious higher oligomers formed, and the dimer species is much smaller than the complexes. We now also include the results of the linker-GH2 run at 200 µM, which showed the same s~20,w~-value of 1.4 as at the low concentration, corresponding to a monomer ([Figure 7---figure supplement 1E](#fig7s1){ref-type="fig"}). These new analyses and data together show that the linker-GH2 and HCBD do not tend to form large homo-oligomers or aggregate under our experimental conditions. Additionally, we can rule out that the HCBD alone aggregates, based on the fact that it does not aggregate in the presence of the GH2 or linker-GH2 mutants. Although we do not have high-concentration sedimentation information on GH2, we feel it is unlikely to oligomerize on its own, given that the linker-GH2 construct does not oligomerize at high concentrations.

*[Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}. I am not an AUC expert, but I found the normalization of the traces to the highest value quite confusing. Why not normalize the traces to the total area under the curves for a better comparison of the fraction size of each peak? When looking at the majority of the traces, discrete s20 species are apparent. Can these be assigned to monomers, dimers, trimers, tetramers and pentamers? Is the weighted average sedimentation coefficient really the best means to analyze AUC runs with such distinct species?*

We agree with the reviewer regarding normalization, and have revised these figures using the normalization strategy suggested by the reviewer. Regarding the assignment of monomer, etc., that could be done, but would be highly speculative, as these "species" could represent time-averaged sedimentation coefficients of rapidly associating and dissociating complexes, the s-values of which are not represented well by the appearances of the curves. The weighted s-values therefore are an accurate and succinct way to describe the overall behavior of the system.

*[Figure 6](#fig6){ref-type="fig"}: \'In these cells, a fraction of PlexinD1 was incompletely processed and remained in the ER or Golgi apparatus.\' What is this assumption based on? Please provide the data.*

A figure of immune-staining of PlexinD1 with an anti-PlexinD1 antibody is included in [Figure 8---figure supplement 1B](#fig8s1){ref-type="fig"}. It is clear that a portion of PlexinD1 remained in the peri-nuclear region.

*Generally: I find it important if the method of structure solution (e.g. molecular replacement with what?), the diffraction limit of the crystals and the R~work~/R~free~ are shortly mentioned for every structure referred to in the manuscript to immediately provide a measure of the quality of the structure, without having to refer to the data collection table.*

We now mention the diffraction limit of the structures in the text.

*[Figure 1](#fig1){ref-type="fig"}: The GIPC structure has several completely new features that should be more thoroughly described and analysed. Please enlarge the figures as much as possible that details can be better recognized. Please provide a topology plot (with all secondary structure elements labelled) of the dimeric GIPC structure to better understand the domain architecture, organization and the domain swap of GIPC. In the supplement, please provide structural comparisons of the GH1 and GH2 domains to related domains in other proteins (e.g. ubiquitin, etc.) to better describe their structural relationships. Also, a one sentence description of the PDZ domain architecture should be included in the text. In the close-ups, please label the indicated residues and indicate more secondary structure element, N and C-termini and use colors that have contrast (for example, a light green secondary structure on a yellow surface is not suited). In printouts, it is generally difficult to recognize much below semi-transparent surfaces, especially in small figures as those in the manuscript. Why not use a proper surface representation with some more contrast and provide additional figures to specifically show residues involved in intra- and intermolecular interactions (ideally with a minimum of additional secondary structure elements in the background -- better remove it instead of fading it out). Include properly labelled surface conservation plots of the domains to better visualize which contact areas are conserved and which are not.*

These are great suggestions. Accordingly, we have implemented the following changes in the revised manuscript: (1) Split [Figure 1](#fig1){ref-type="fig"} into two. In new [Figure 1](#fig1){ref-type="fig"}, we now include expanded views of the GH1 domain-swapped dimer, the PDZ domain and the linker-GH2 domain. These new panels illustrate the architecture of each domain clearly. We attempted to draw a topology model, which turned out to be quite confusing and therefore decided not to show it. (2) New [Figure 2](#fig2){ref-type="fig"} now show enlarged view of the auto-inhibitory interactions mediated by the linker-GH2 domains. (3) Included a sentence to describe the overall structure of the PDZ domain. (4) Included more labels such as for N- and C-termini of domains.

*Discuss the domain swap: Would a monomeric GIPC be stable or would the removal of one monomer lead to a collapse of the GH1 domain? Is there a structural possibility to envisage a monomeric GIPC, e.g. one without domain swap, for example, when the polypeptide chain is newly synthesized?*

The description regarding this point is in the Methods section of the original manuscript. When expressed in *E. coli*, monomeric GIPCs could form, but was unstable. It is hard to speculate whether there is a portion of monomers of GIPCs in eukaryotic cells, but the dimeric nature of GIPCs has been well established by previous studies as cited in the manuscript.

*[Figure 2](#fig2){ref-type="fig"}. Although the structure of the plexin cytoplasmic domain has been described before, it still would be helpful for the casual reader to properly describe the domain architectures of the crystallized constructs here. For example, mention that the GAP domain is constituted from C1 and C2 and has a fold related to RasGAPs. Describe in more detail which structures of plexins have been determined before and how do they compare to the current structure. Add \'mouse PlexinD1\' in [Figure 2A](#fig2){ref-type="fig"}, indicate the boundaries of the crystallized construct below, indicate in [Figure 2B](#fig2){ref-type="fig"} which structure is the apo and which the GIPC-bound form (the figure should be self-explanatory without reading the legend). Use separate colors for the C1, RBD, C2 domains, indicate the binding sites for small GTPases (are they accessible in these structures for small G protein binding?), indicate N- and C-termini of the construct. Label the tail segments. In the close-ups of [Figure 2C](#fig2){ref-type="fig"}, it is hard to recognize anything, the interacting residues in the GH1 and PDZ domain are almost invisible: Remove any non-essential detail (for example, the electron densities in the left figures), better concentrate on visualizing the contacts instead. Indicate relevant additional secondary structure elements, show surface conservation plots in the supplement to visualize whether interacting residues are conserved in plexins and GIPCs. Properly label [Figure 2F](#fig2){ref-type="fig"} to indicate which constructs have been superimposed.*

*From an aesthetical point of view: The secondary structure representations in the [Figure 2C](#fig2){ref-type="fig"} close-up look ugly: The two helices of the PlxD1 on the left should be separated by a short loop, and the two strands of the PDZ domain look twisted and weird. Manually re-assign secondary structure elements in pymol and chose another, higher quality strand representation in pymol.*

These are great suggestions and we have implemented most of them. Particularly, we have split [Figure 2](#fig2){ref-type="fig"} into two figures (now [Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}), and made most of the panels bigger. The PBM/GIPC1 interface is now illustrated with two panels, one with surface representation and another with a detailed view of interacting residues.

*[Figure 3](#fig3){ref-type="fig"}: I would recommend to first describe the two assembly interfaces in detail in the text and then refer to the higher order assembly, it is rather confusing and counter-intuitive as it is now. Again, the involved amino acids are difficult to recognize in the semi-transparent surface representation in [Figure 3B](#fig3){ref-type="fig"} -- either remove the surface or provide two separate figures.*

*Please provide superpositions of all five GH2-HCBD complex in the ASU in the supplement (including the complex that links the two ASUs). Are they really completely identical? Any structure-based hypothesis why oligomerization in AUC stops at the tetramer/pentamer level? For example, would a related closed tetrameric/pentameric assembly be possible (with some minor reorientation of the assembly sites)?*

*It is distracting that the mutagenesis data appear at the end of the results, whereas the residues participating in the assembly are described much earlier. The authors may consider including the mutagenesis/AUC data immediately after describing the relevant structural data. For example, some AUC data of [Figure 5](#fig5){ref-type="fig"} would neatly fit below [Figure 3](#fig3){ref-type="fig"}. [Figure 4](#fig4){ref-type="fig"}, [Figure 6](#fig6){ref-type="fig"} and some AUC data from [Figure 5](#fig5){ref-type="fig"} may be merged in one coherent figure describing the assembly of the Plexin-GIPC-myosin complex.*

We have enlarged the panels in [Figure 3](#fig3){ref-type="fig"} (new [Figure 5](#fig5){ref-type="fig"}) showing the interfaces to make them more clear. We have included a supplemental figure to show that both interfaces I and II made by the different promoters in the crystals are essentially the same in both GIPC1-GH2/myosin VI and GIPC2-GH2/myosin VI structures ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). As mentioned in the original manuscript, pressure induced by high centrifugation force has been shown to inhibit long, linear polymers, which may explain the lack of large oligomers in the AUC experiments. Due to the complexity of the paper, both ways of arranging the data and text have their pros and cons, we prefer to keep as it is.

*[Figure 5](#fig5){ref-type="fig"} bottom: Please provide the exact amino acid exchanges of all mutants (numbers) in the figure, not in the legend.*

Done.

*[Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}: Very nice figure, but difficult to recognize on a black background. Why not chose different colors for neighboring ASUs (at least for the colored filament) to better visualize how the continuous filament is formed by adjacent ASUs.*

We have changed the background to white. We prefer to use different colors for the GIPC-GH2 and myosin VI-HCBD to illustrate the alternating pattern. Instead of using different colors for different ASUs, we now label the three ASUs that form the colored filament to highlight how they connect to each other.

*[Figure 7](#fig7){ref-type="fig"}: Please label the individual domains of GIPC in the figure (ideally with the corresponding domain colors). Discuss: How do the GIPC-PlxD1 hetero-tetramers relate to the GIPC-myosin oligomer? Do the authors envisage a further 3D cross-linking by the combination of tetramers and oligomers or could the tetramers assemble along the oligomeric GIPC-myosin filament?*

We have labelled the domains in GIPC in [Figure 7](#fig7){ref-type="fig"} as suggested. Due to the flexibility of the linkers in both GIPC and myosin VI, both types of interactions are geometrically possible. The Discussion section of the manuscript mentioned the 2D cross-linking possibility (3D if one considers the longitudinal plexin/GIPC/myosin interactions as another dimension). We did not get into details of this point because the actual size and organization of oligomers likely vary depending on the shape of receptor dimers and curvature of vesicles.

*[Table 1](#tbl1){ref-type="table"}: Please indicate in addition the contents of the ASU, e.g. 1 dimeric GIPC complex, 2 GIPC/plexin dimers, etc.*

Done.

*[Table 2](#tbl2){ref-type="table"}: Please provide an additional main figure showing the site of disease-related mutations in the auto-inhibited or liganded GIPC structure and discuss the implications in more detail. This information is most relevant for many medical researchers.*

Great suggestion. A new figure ([Figure 10](#fig10){ref-type="fig"}) is now included.

[^1]: ^\*^Numbers in parenthesis are for the highest resolution shell.

[^2]: \# CC~1/2~ values shown are for the highest resolution shell.
